TY - BOOK PY - 2015 DA - 2015// TI - Council conclusions on Personalised medicine for patients ID - ref1 ER - TY - JOUR AU - Druker, B. J. AU - Tamura, S. AU - Buchdunger, E. PY - 1996 DA - 1996// TI - Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells JO - Nat Med VL - 2 UR - https://doi.org/10.1038/nm0596-561 DO - 10.1038/nm0596-561 ID - Druker1996 ER - TY - JOUR AU - Chapman, P. B. AU - Hauschild, A. AU - Robert, C. PY - 2011 DA - 2011// TI - Improved survival with vemurafenib in melanoma with BRAF V600E mutation JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1103782 DO - 10.1056/NEJMoa1103782 ID - Chapman2011 ER - TY - JOUR AU - Lin, P. H. AU - Li, H. Y. AU - Fan, S. C. PY - 2017 DA - 2017// TI - A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice JO - Cancer Med VL - 6 UR - https://doi.org/10.1002/cam4.969 DO - 10.1002/cam4.969 ID - Lin2017 ER - TY - JOUR AU - Zugazagoitia, J. AU - Rueda, D. AU - Carrizo, N. PY - 2017 DA - 2017// TI - Prospective clinical integration of an amplicon-based next-generation sequencing method to select advanced non-small-cell lung Cancer patients for genotype-tailored treatments JO - Clin Lung Cancer VL - 19 UR - https://doi.org/10.1016/j.cllc.2017.06.008 DO - 10.1016/j.cllc.2017.06.008 ID - Zugazagoitia2017 ER - TY - STD TI - Van den Bulcke M, San Miguel L, Salgado R et al. Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology. Synthesis. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE) reports 240Cs. D/2015/10.273/25. http://kce.fgov.be/sites/default/files/page_documents/KCE_240_Targeted%20therapy_Scientific%20Report.pdf. UR - http://kce.fgov.be/sites/default/files/page_documents/KCE_240_Targeted%20therapy_Scientific%20Report.pdf ID - ref6 ER - TY - JOUR AU - Hébrant, A. AU - Froyen, G. AU - Maes, B. PY - 2017 DA - 2017// TI - The Belgian next generation sequencing guidelines for haematological and solid tumours JO - Belg J Med Oncol VL - 11 ID - Hébrant2017 ER - TY - JOUR AU - Hébrant, A. AU - Van Valckenborgh, E. AU - Salgado, R. PY - 2018 DA - 2018// TI - Opportunities and challenges in oncology and molecular testing: the Belgian strategy JO - Belg J Med Oncol. VL - 12 ID - Hébrant2018 ER - TY - JOUR AU - Lolkema, M. P. AU - Gadellaa-van Hooijdonk, C. G. AU - Bredenoord, A. L. PY - 2013 DA - 2013// TI - Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.45.2789 DO - 10.1200/JCO.2012.45.2789 ID - Lolkema2013 ER -